Connect Biopharma vs Upstream Bio
CNTB and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNTB and UPB compare
Connect Biopharma grew revenue faster over the last twelve months (50.3% versus 16.0% for Upstream Bio).
Connect Biopharma keeps more of each dollar of sales as profit, with a net margin of −2336% compared with −4956% at Upstream Bio.
Upstream Bio scores higher on the StockData Score (9 against 6 for Connect Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNTB | UPB |
|---|---|---|
| Size and price | ||
| Market cap | – | $187M |
| Share price | $0.802 | $3.41 |
| Change, 1 year | −49.3% | −85.9% |
| Change, 5 years | −94.9% | – |
| Beta (5Y) | 0.53 | 1.47 |
| Employees | – | 75 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 59.1× |
| P/B | – | 0.7× |
| Growth | ||
| Revenue growth (TTM) | 50.3% (better) | 16.0% |
| Profitability | ||
| Operating margin | −2384% (better) | −5383% |
| Net margin | −2336% (better) | −4956% |
| FCF margin | −2053% | – |
| Return on equity | −141% | −46.0% (better) |
| Return on invested capital | – | −1082% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.37 | 27.99 (better) |
| Altman Z-score | – | 8.07 |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 22.1% | 92.3% |
| Held by insiders | 31.6% | 8.6% |
| Insider net buying, 12 months | $4.4M (better) | −$105K |
| Short interest, % of float | – | 9.0% |
Go deeper
- CNTB stock overview
- CNTB income statement
- CNTB valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.